125 related articles for article (PubMed ID: 18083750)
1. Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
Negredo E; Puigdomènech I; Marfil S; Puig J; Pérez-Alvarez N; Ruiz L; Rey-Joly C; Clotet B; Blanco J
J Antimicrob Chemother; 2008 Feb; 61(2):400-4. PubMed ID: 18083750
[TBL] [Abstract][Full Text] [Related]
2. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
Negredo E; Clotet B; Puig J; Pérez-Alvarez N; Ruiz L; Romeu J; Moltó J; Rey-Joly C; Blanco J
AIDS; 2006 Feb; 20(4):619-21. PubMed ID: 16470128
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy.
Fredriksen J; Ueland T; Dyrøy E; Halvorsen B; Melby K; Melbye L; Skalhegg BS; Bohov P; Skorve J; Berge RK; Aukrust P; Frøland SS
Eur J Clin Invest; 2004 Oct; 34(10):709-15. PubMed ID: 15473896
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
6. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
8. Effects of highly active antiretroviral therapy on paediatric metabolite levels.
Rhoads MP; Smith CJ; Tudor-Williams G; Kyd P; Walters S; Sabin CA; Lyall EG
HIV Med; 2006 Jan; 7(1):16-24. PubMed ID: 16313288
[TBL] [Abstract][Full Text] [Related]
9. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
10. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
[TBL] [Abstract][Full Text] [Related]
11. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
12. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF;
J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
15. IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads.
Lozano JM; Kindelán JM; Cabello A; Gonzalez R; Solana R; Peña J
Int Immunopharmacol; 2006 Jun; 6(6):1034-8. PubMed ID: 16644491
[TBL] [Abstract][Full Text] [Related]
16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
17. Excess apoptosis of mononuclear cells contributes to the depressed cytomegalovirus-specific immunity in HIV-infected patients on HAART.
Weinberg A; Jesser RD; Edelstein CL; Bill JR; Wohl DA
Virology; 2004 Dec; 330(1):313-21. PubMed ID: 15527856
[TBL] [Abstract][Full Text] [Related]
18. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life.
Viganò A; Trabattoni D; Schneider L; Ottaviani F; Aliffi A; Longhi E; Rusconi S; Clerici M
J Pediatr; 2006 Mar; 148(3):389-91. PubMed ID: 16615974
[TBL] [Abstract][Full Text] [Related]
19. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
20. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
Sagot-Lerolle N; Lamine A; Chaix ML; Boufassa F; Aboulker JP; Costagliola D; Goujard C; Pallier C; Delfraissy JF; Lambotte O;
AIDS; 2008 Jun; 22(10):1125-9. PubMed ID: 18525257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
